2616.HK WACC - Weighted Average Cost of Capital

The WACC of CStone Pharmaceuticals (2616.HK) is 9.4%.

The Cost of Equity of CStone Pharmaceuticals (2616.HK) is 9.70%.

The Cost of Debt of CStone Pharmaceuticals (2616.HK) is 8.90%.

	Range	Selected
Cost of equity	8.40% - 11.00%	9.70%
Tax rate	22.10% - 22.30%	22.20%
Cost of debt	7.00% - 10.80%	8.90%
WACC	8.1% - 10.7%	9.4%

WACC

2616.HK WACC calculation

Category	Low	High

Long-term bond rate	2.9%	3.4%
Equity market risk premium	6.0%	7.0%
Adjusted beta	0.93	1.02

Additional risk adjustments	0.0%	0.5%
Cost of equity	8.40%	11.00%

Tax rate	22.10%	22.30%
Debt/Equity ratio	0.1	0.1
Cost of debt	7.00%	10.80%

After-tax WACC	8.1%	10.7%


Selected WACC	9.4%

2616.HK's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for 2616.HK:

cost_of_equity (9.70%) = risk_free_rate (3.15%) + equity_risk_premium (6.50%) * adjusted_beta (0.93) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.